See also this year's filing and all EDGAR filings for this company.
PDF Report 0001005201_2019_Assertio_Therapeutics_Inc.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | Missing logo | subcommand.report | {} |
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.6848854121920522, 'aggregate_val': 712531000, 'exp_sum': 265386000, 'exp_to_value': {'LiabilitiesCurrent': 246036000, 'LiabilitiesNoncurrent': 19350000, 'remainder_Liabilities': 0}} |
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.3723216001132537, 'aggregate_val': 469212000, 'exp_sum': 197786000, 'exp_to_value': {'LiabilitiesCurrent': 184553000, 'LiabilitiesNoncurrent': 13233000, 'remainder_Liabilities': 0}} |
Graph
Absolute values for 0001005201, Assertio Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 208,107,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 692,099,000 |
| 2 | PropertyPlantAndEquipmentNet | 13,064,000 |
| 3 | remainder_Assets | 19,596,000 |
| 4 | LiabilitiesCurrent | 246,036,000 |
| 5 | LiabilitiesNoncurrent | 19,350,000 |
| 6 | remainder_Liabilities | 447,145,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 88,776,595 |
| 9 | ResearchAndDevelopmentExpense | 8,163,750 |
| 10 | remainder_Expenses | 210,919,260 |
| 11 | remainder_Revenues | 321,283,665 |
| 12 | remainder_NetIncome | 685,870,848 |
| 13 | remainder_ComprehensiveNetIncome | 3,694 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 932,866,000 |
| 1 | Liabilities | 712,531,000 |
| 2 | Expenses | 307,859,605 |
| 3 | Revenues | 321,283,665 |
| 4 | StockholdersEquity | 220,335,000 |
| 5 | NetIncome | 699,294,908 |
| 6 | ComprehensiveNetIncome | 699,296,755 |
| 7 | BaseVar | 1,480,207,406 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.43 |
| 9 | EconomicCapitalRatio | 2.63 |